Given the importance of establishing the memory feature in cancer immunotherapy that provides long-term treatment benefits, we examined the percentage of effector memory CD4+ (CD3+CD4+CD44+CD62L- cells) and CD8+ T cells (CD3+CD8+CD44+CD62L- cells) in splenocytes of treated mice. This evidence concerns the gene CD44 and cancer.